Analytical specificity of commercially available methods for serum phenytoin determination.

Phenytoin concentrations in serum obtained from uremic patients and patients with normal renal function were measured by fluorescence polarization immunoassay (FPI), rate nephelometric inhibition immunoassay ( RNII ), and homogeneous enzyme immunoassay (EIA) and compared to corresponding values determined by high performance liquid chromatography (HPLC). In serum specimens from patients with normal renal function, phenytoin concentrations measured by FPI, RNII , and EIA averaged within 12% of the corresponding concentrations determined by HPLC. Phenytoin concentrations in uremic serum were 20% (FPI), 60% (EIA), and 83% ( RNII ) higher than corresponding values determined by HPLC. Accumulation of phenytoin metabolites in patients with end-stage renal disease was associated with artifactually elevated measured serum concentrations of phenytoin. FPI was the most specific of the three commercial methods evaluated.

[1]  D. Olive,et al.  Fluorescence polarization immunoassay IV. Determination of phenytoin and phenobarbital in human serum and plasma. , 1982, Clinical chemistry.

[2]  M. Jolley.  Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. , 1981, Journal of analytical toxicology.

[3]  G. Matzke,et al.  Elevated Serum Phenytoin Concentrations in a Uremic Patient When Measured by Enzyme-Multiplied Immunoassay , 1981, Drug intelligence & clinical pharmacy.

[4]  D. S. Kabakoff,et al.  Metabolite interference in homogeneous enzyme immunoassay of phenytoin. , 1981, Clinical chemistry.

[5]  P. Finley,et al.  Rate-nephelometric inhibition immunoassay of phenytoin and phenobarbital. , 1981, Clinical chemistry.

[6]  R. Sawchuk,et al.  Liquid-chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in plasma and urine. , 1980, Clinical chemistry.

[7]  J. Rasmussen,et al.  Renal disease may increase apparent phenytoin in serum as measured by enzyme-multiplied immunoassay. , 1980, Clinical chemistry.

[8]  D. M. McDonald,et al.  Renal disease may increase apparent phenytoin in serum as measured by enzyme-multiplied immunoassay. , 1980, Clinical chemistry.

[9]  D. Daly,et al.  Inheritance of phenytoin hypometabolism: A kinetic study of one family , 1980, Clinical pharmacology and therapeutics.

[10]  J. Hull.  The Effect of Disease States on Drug Pharmacokinetics , 1977 .

[11]  T. Ludden,et al.  Individualization of phenytoin dosage regimens , 1977, Clinical pharmacology and therapeutics.

[12]  H. Vainio.  LINKAGE OF MICROSOMAL DRUG OXIDATION AND GLUCURONIDATION , 1976 .

[13]  J. Penry,et al.  Usefulness of blood levels of antiepileptic drugs. , 1974, Archives of neurology.

[14]  H. Booker,et al.  Serum Concentrations of Free Diphenylhydantoin and their Relationship To Clinical Intoxication , 1973, Epilepsia.

[15]  E. F. Ullman,et al.  "Homogeneous" enzyme immunoassay. A new immunochemical technique. , 1972, Biochemical and biophysical research communications.

[16]  F. Sjöqvist,et al.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia. , 1970, Lancet.

[17]  J. Haynes,et al.  Some causes of ineffectiveness of diphenylhydantoin. , 1966, Archives of neurology.